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Abstract: Background: Estimates of the burden of antimicrobial resistance (AMR) are needed to
ascertain AMR impact, evaluate interventions and to allocate resources efficiently.
Recent studies have estimated health, cost and economic burden relating to AMR, with
outcomes of interest ranging from drug-bug resistance impact on mortality in a hospital
setting to total economic impact of AMR on the global economy. However, recent
collation of this information has been largely informal, with no formal quality
assessment of the current evidence base (e.g. with predefined checklists). This review
therefore aims to establish what perspectives and resulting methodologies have been
used in establishing the burden of AMR, whilst also ascertaining the quality of these
studies.
Methods: The literature review will identify relevant literature using a systematic review
methodology. MEDLINE, EMBASE, Scopus and EconLit will be searched utilising a
predefined search string. Grey literature will be identified by searching within a
predefined list of organisational websites. Independent screening of retrievals will be
performed in a two-stage process (abstracts and full texts), utilising a pre-defined
inclusion and exclusion criteria. Data will be extracted into a data extraction table and
descriptive examination will be performed. Study quality will be assessed using the
Newcastle-Ottawa scales and the Philips checklists where appropriate. A narrative
synthesis of the results will be presented.
Discussion: This review will provide an overview of previous health, cost and economic
definitions of burden and the resultant impact of these different definitions on the
burden of AMR estimated. The review will also explore the methods that have been
used to calculate this burden and discuss resulting study quality. This review can
therefore act as a guide to methods for future research in this area.
Trial Registration: This review has been registered with the PROSPERO International
Prospective Register of systematic reviews, registration number CRD42016037510.
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Response to Reviewers: Dear Dr Woolacott,
Many thanks for your letter, we agree with the additional comments and are looking
forward to being published in Systematic Reviews. We have detailed any changes
below, as well as highlighted by tracked changes on the word document.
Best Wishes,
Nichola
1.Q: The amended abstract now fails to include any mention of independent screening
and selection of articles for inclusion in the review.
A: We have changed line 45 of the abstract to “Independent screening of retrievals will
be performed in a two-stage process (abstracts and full texts), utilising a pre-defined
inclusion and exclusion criteria”, in order to highlight screening is independent.
2.Q: The article fails to mention any measures to ensure the quality of data extraction.
data extraction should be conducted independently induplicate or, if that is not
considered feasible, it should be independently checked.
A: We have changed line 165 to “Data will be inputted into a standardised data
extraction table (Excel) and independently checked to ensure quality”.
Any additional changes that can be undone by the editor if seen fit:
Added a “,” in line 69 to help sentence structure.
Line 103, changed “looked” to “aim”.
Line 104, changed “included” to “includes”
Line 216, Funding paragraph was changed to meet NIHR policy to; “The research was
funded by the National Institute for Health Research Health Protection Research Unit
(NIHR HPRU) in Healthcare Associated Infections and Antimicrobial Resistance at
Imperial College London in partnership with Public Health England (PHE). The views
expressed are those of the author(s) and not necessarily those of the NHS, the NIHR,
the Department of Health or Public Health England.”
Table 1; “Both sexes” changed to “All sexes” so as to not exclude anyone with gender
identifiability differences etc.
Figure 1; I noticed “retrievals” in the OVID box was cut off so have increased
accordingly.
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Abstract 31 
Background: Estimates of the burden of antimicrobial resistance (AMR) are needed 32 
to ascertain AMR impact, evaluate interventions and to allocate resources efficiently. 33 
Recent studies have estimated health, cost and economic burden relating to AMR, 34 
with outcomes of interest ranging from drug-bug resistance impact on mortality in a 35 
hospital setting to total economic impact of AMR on the global economy. However, 36 
recent collation of this information has been largely informal, with no formal quality 37 
assessment of the current evidence base (e.g. with predefined checklists). This 38 
review therefore aims to establish what perspectives and resulting methodologies 39 
have been used in establishing the burden of AMR, whilst also ascertaining the 40 
quality of these studies. 41 
Methods: The literature review will identify relevant literature using a systematic 42 
review methodology. MEDLINE, EMBASE, Scopus and EconLit will be searched 43 
utilising a predefined search string. Grey literature will be identified by searching 44 
within a predefined list of organisational websites. Independent sScreening of 45 
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retrievalssults will be performed in a two-stage process (abstracts and full texts), 46 
utilising a pre-defined inclusion and exclusion criteria. Data will be extracted into a 47 
data extraction table and descriptive examination will be performed. Study quality will 48 
be assessed using the Newcastle-Ottawa scales and the Philips checklists where 49 
appropriate. A narrative synthesis of the results will be presented. 50 
Discussion: This review will provide an overview of previous health, cost and 51 
economic definitions of burden and the resultant impact of these different definitions 52 
on the burden of AMR estimated. The review will also explore the methods that have 53 
been used to calculate this burden and discuss resulting study quality. This review 54 
can therefore act as a guide to methods for future research in this area. 55 
Trial Registration: This review has been registered with the PROSPERO 56 
International Prospective Register of systematic reviews, registration number 57 
CRD42016037510. 58 
Keywords: Antimicrobial resistance, Burden, Methods, Systematic Review 59 
Background 60 
Antimicrobial resistance (AMR) can be defined as the phenomenon in which 61 
microorganisms persist in the presence of antimicrobials, which are commonly used 62 
to prevent and/or treat infectious disease. AMR is a cause for concern within the UK 63 
and globally, due to the current and great potential negative impact on population 64 
health [1] [2]. AMR associated burden can be defined as AMR impact on health 65 
(mortality or morbidity), impact on healthcare and patient costs or impact on the 66 
economy (labour force impact, productivity impact or opportunity cost) depending on 67 
study perspective. The AMR Review, chaired by Jim O’Neill, has recently published 68 
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estimates of potential future AMR burden, for example stating global Gross Domestic 69 
Product (GDP) loss over the next 40 years could be as great as $3 trillion [1]. These 70 
estimates have since been cited by policy makers and the media [3] [4], showing the 71 
demand for estimates quantifying the current and potential future problem AMR 72 
poses. Accurate estimates of disease related burden are needed for policy makers to 73 
establish disease related resource need, to advocate for appropriate levels of 74 
funding and are critical inputs for any health economic evaluations of AMR 75 
interventions.  76 
Recent descriptive review articles have discussed methods of burden estimation in 77 
the context of AMR, citing a few articles as examples of different methodologies [5] 78 
[6] [7]. However, since the 2012 rapid review update of a previous systematic review 79 
[8] [9], there has been no systematic review which looks into the estimation of 80 
burden associated with AMR. None of the aforementioned reviews formally quality 81 
assess study methodology, which is needed to highlight methodological issues in 82 
establishing the burden of AMR. The 2012 rapid review by Smith and Coast [8] 83 
concluded that the evidence base suggests the burden of AMR is relatively modest 84 
due to the narrow perspective taken by most studies, and that a wider societal 85 
perspective was needed to capture the true impact. However, with more recent work 86 
taking a wider perspective on AMR burden [1] and many more research articles 87 
being published in this area in recent years, a new assessment is required of the 88 
current estimates of both health and economic AMR burden.  89 
The aims of this systematic review include; (i) to establish what perspectives and 90 
resulting methodologies have been used in establishing the burden of AMR, (ii) to 91 
see how this impacts on the burden estimates given and (iii) to assess the quality of 92 
these studies.  93 
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Methods/Design 94 
Research question 95 
What perspectives and resulting methodologies have been used in establishing the 96 
burden of AMR? 97 
Study Overview 98 
Figure 1 depicts an overview of the study procedure. 99 
<Figure can be found at the end of the document – to be placed here or similar in 100 
final manuscript> 101 
Study eligibility 102 
Any studies that aimlooked to quantify the burden of AMR within humans will be 103 
considered in this review, this includesd studies across any microbes, infections and 104 
country settings. 105 
The modified PICO [10] inclusion and exclusion criteria to be applied at the review 106 
stages can be found in Table 1.  107 
<Table can be found at the end of the document – to be placed here or similar in 108 
final manuscript> 109 
Search strategy 110 
The methods used in this systematic review are in line with the PRISMA guidelines 111 
[11]. In line with previous published protocols [12], a completed copy of the PRISMA-112 
P checklist has been completed [see Additional file 1]. 113 
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The search period will be restricted from 2013 onwards, this date was chosen to 114 
avoid retrieval duplication with Smith & Coast [8]. Ovid ‘Medline & EMBASE’, Scopus 115 
and EconLit will be searched, along with grey literature from predetermined agency 116 
websites. The following agency websites were defined after consulting a group of 117 
AMR researchers. Their content will be searched for reports and articles relating to 118 
the population of interest: 119 
 Public Health England 120 
 Public Health Wales 121 
 Health Protection Scotland 122 
 NHS Health Scotland 123 
 Department of Health (UK) 124 
 Health Protection Agency  125 
 National Institute for Health and Care Excellence  126 
 Centers for Disease Control and Prevention  127 
 World Health Organisation 128 
 European Commission for Public Health 129 
 Review on Antimicrobial Resistance 130 
It has been previously stated that many papers do not mention AMR generally, but 131 
rather specific microbes [8]. In an attempt to tackle this, an additional 13 clinically 132 
relevant bacteria will be highlighted in the search. These can be identified in the 133 
stated search string below: (note that this is in the format for Scopus, the same terms 134 
are to be reformatted for OVID and EconLit searchs):  135 
( ( TITLE ( ( excess  OR  associated  OR  attributable )  W/2  ( burden  OR  morbidity  136 
OR  mortality  OR  cost* ) )  OR  ABS ( ( excess  OR  associated  OR  attributable )  137 
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W/2  ( burden  OR  morbidity  OR  mortality  OR  cost* ) ) )  OR  ( TITLE ( ( economic  138 
OR  clinical  OR  global )  W/2  ( impact  OR  outcome*  OR  burden  OR  cost* ) )  139 
OR  ABS ( ( economic  OR  clinical  OR  global )  W/2  ( impact  OR  outcome*  OR  140 
burden  OR  cost* ) ) ) )  AND  ( ( ALL ( ( "antibiotic"  OR  "antimicrobial"  OR  141 
"multidrug"  OR  "microbial-drug" )  PRE/1  resistan* ) )  OR  ( ( TITLE ( enterococc*  142 
OR  escherichia  OR  streptococc*  OR  staphylococc*  OR  klebsiealla  OR  143 
pseudomonas  OR  neisseria  OR  chlamydia  OR  clostridi*  OR  mycobacteri*  OR  144 
"gram-positive"  OR  "gram-negative" )  OR  ABS ( enterococc*  OR  escherichia  OR  145 
streptococc*  OR  staphylococc*  OR  klebsiealla  OR  pseudomonas  OR  neisseria  146 
OR  chlamydia  OR  clostridia*  OR  mycobacteri*  OR  "gram-positive"  OR  "gram-147 
negative" ) )  AND  ( ( TITLE ( susceptib*  OR  nonsusceptib*  OR  resistan* )  OR  148 
ABS ( susceptib*  OR  nonsusceptib*  OR  resistan* ) )  OR  ( ALL ( ( "antibiotic"  OR  149 
"antimicrobial"  OR  "multidrug"  OR  "microbial-drug" )  PRE/1  resistan* ) ) ) ) ) 150 
The lead reviewer (NN) will review all abstracts and full texts. Independent reviewers 151 
will perform a parallel review of the abstracts and full texts, with each of these 152 
reviewers being assigned a percentage of the total retrieval items. Any discrepancies 153 
will be discussed and re-examined until agreement is reached.   154 
Quality Assessment 155 
Risk of bias in individual studies will be assessed using the Newcastle-Ottowa scales 156 
for cohort and case control studies [13], whilst the Philips checklist will be used for 157 
economic models [14]. These tools were chosen as the focus of this review is on 158 
study methodology rather than reporting standards.  159 
Risk of bias across studies will be assessed in two groups; studies looking at health 160 
burden and studies looking at all other burden, and will simply be assessed based on 161 
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the sign and significance of the outcome. This is due to the expected heterogeneity 162 
in studies (outcome, infection, resistance). 163 
Data Collection and Analysis 164 
Data will be collected by the lead reviewer (NN). Data will be inputted into a 165 
standardised data extraction table (Excel) and independently checked to ensure 166 
quality.  167 
The following information will be extracted: study identifiers, study characteristics 168 
(perspective, country setting), population characteristics, data setting (hospital or 169 
community), study methodology, outcome of interest (mortality, length of stay, cost), 170 
results (e.g. resistance has a significant impact on the outcome of interest), stated 171 
limitations and information used for risk of bias assessment (informed by the cited 172 
checklists). 173 
A descriptive synthesis of the study information and risk of bias, structured around 174 
the perspectives (health, health system and economic burden) and related methods 175 
used will be provided. This will include a results table containing individual level 176 
study data, and summary graphical representation of study characteristics such as 177 
scatter plots of estimates for excess mortality and monetary cost. We anticipate 178 
limited scope for a meta-analysis given the assumed heterogeneous nature of 179 
identified outcomes, studies included may differ across perspective, infection site, 180 
infection type/causative organism, bug-drug combinations and sub-populations. 181 
However, if there are suitable data for one drug-bug combination in similar 182 
populations, then Forest plots will be constructed utilising hazard ratio as the 183 
comparative outcome [15].   184 
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The format of this write-up will be a manuscript which will be submitted for 185 
publication in a peer-reviewed journal, it will also contribute to the lead reviewer’s 186 
(NN) PhD project as part of the National Institute for Health Research Health 187 
Protection Research Unit (NIHR HPRU) in Healthcare Associated Infections and 188 
Antimicrobial Resistance. 189 
Discussion 190 
Recent estimates for the burden suggest that AMR that it is a significant economic 191 
burden to the global economy [1], whilst previous reviews have suggested that 192 
perhaps study outcome and methodology impacts whether AMR is found to have a 193 
significant burden or not [8]. Yet, there has been no literature review which formally 194 
looks to assess the quality of such studies. 195 
Originally the leading author ran a similar search strategy independently, however, 196 
after discussion with co-authors it was realised that given the nature of previous 197 
reviews, and the lack of quality assessment of previous literature, the original study 198 
design did not adequately answer the research question or fill the current research 199 
gap. Therefore the original study was halted (results not published in peer-review) 200 
and the study protocol was revised into the protocol written here.  201 
This review will provide an overview of previous health, cost and economic 202 
definitions of burden in the context of AMR. The review will also explore the methods 203 
that have been used to calculate this burden and discuss resulting study quality. This 204 
review can therefore act as a guide to methods for future research. 205 
List of Abbreviations 206 
AMR – Antimicrobial Resistance 207 
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GDP – Gross Domestic Product 208 
PICO – Population, Intervention, Comparison, Outcome. 209 
UK – United Kingdom 210 
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Table 1: Inclusion/Exclusion Criteria 
Criteria Inclusion Exclusion 
Population   Humans Animals 
All ages Plants 
AllBoth sexes  
Infection with antimicrobial resistant organism   
Intervention 
Not Applicable Not Applicable 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
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15 
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18 
19 
20 
21 
22 
23 
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26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
Comparator 
Not Applicable Not Applicable 
Outcomes Associated Health burden, to include but not restricted to:  
Morbidity; for example excess Length of Stay in hospital. 
Mortality. 
Health-Related Quality of Life only 
Associated Healthcare cost burden, to include but not 
restricted to:  
Resource use 
Opportunity cost 
Molecular biology only 
Economic burden, to include but not restricted to: 
Costs associated with loss of productivity and reduced 
labour force 
Work-loss hours per/case episode 
Epidemiology only 
Secondary burden from not being able to use antibiotics in 
ways previously or currently used in healthcare, to include 
but not restricted to: 
Reduced surgery 
Reduced use in chemotherapy and similar therapies 
Outcomes associated with the evaluation of an intervention 
such as clinical cure rate only. 
Study 
design 
Case–control studies Editorials 
Cohort studies Letters 
Cross–sectional studies Case series report  
Longitudinal studies Conference abstracts/reports 
Randomised controlled trials Evaluations of treatments/interventions 
Modelling studies Reviews 
Economic Evaluations   
Other  English Language   
 285 
Figure 1: Overview of Study Methodology 286 
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EMBASE) abstract 
retrievals 
Scopus abstract 
retrievals  
EconLit abstract 
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Title & Abstract Review by 
independent reviewers  
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